Delta sleep-inducing peptide
DSIP
Cited range Replication is uneven
What it is
DSIP was isolated in the 1970s from rabbit cerebral venous blood during sleep studies. It became a research object for sleep architecture, withdrawal states, and stress — with inconsistent replication over the following decades.
Benefits in plain language
What researchers and reference users usually mean when they talk about this compound. These are study themes and common claims — not a promise that it will do this in you.
- Delta sleep-inducing peptide is an old research molecule named for sleep-wave changes in animals.
- People reach for it when sleep onset or overnight staying-asleep is the problem.
- It is not a knockout sedative like a sleeping pill. The hope is more natural-feeling sleep architecture.
- Human data are mixed and old. Treat “sleep peptide” marketing with a grain of salt.
If a branded, FDA-approved product exists, that label is the only dose that is actually authorized. Research-chemical vials are a different object.
Mechanism of action
No single modern receptor story is settled. Hypotheses have included modulation of GABAergic and hypothalamic sleep circuits and effects on stress-axis peptides. Treat mechanism text as historical, not locked-in pharmacology.
Possible side effects / caveats
Vivid dreams, next-day grogginess, or paradoxically worse sleep show up in anecdotal writeups. Evidence quality is low. Do not frame DSIP as a validated insomnia drug.
Protocol ranges
| Source tier | Amount | Cadence | Notes |
|---|---|---|---|
| Cited range | 100–300 mcg | Evening, often 1–3 h before intended sleep | Dominant research-community figure |
| Older trials | nmol/kg IV | Study-specific | Not a catalog-vial conversion |